Related Experiment Video

Updated: Nov 20, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.5K

A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine

Narendranath Epperla1, Mehdi Hamadani2,3

  • 1Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.

Current Hematologic Malignancy Reports
|January 25, 2021
PubMed
Abstract

Insights

Camidanlumab tesirine shows promise for relapsed/refractory classical Hodgkin lymphoma patients. This new agent offers encouraging activity and a manageable safety profile, providing a vital new option.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Limited treatment options exist for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who have progressed on brentuximab vedotin and PD-1 inhibitors.
  • Camidanlumab tesirine (Cami) is an emerging therapeutic agent demonstrating potential activity in heavily pretreated cHL patients.

Purpose of the Study:

  • To provide a comprehensive review of Camidanlumab tesirine (Cami) as a treatment option for relapsed/refractory classical Hodgkin lymphoma (cHL).
  • To summarize the safety and efficacy findings from early-phase clinical studies of Cami in cHL.

Main Methods:

  • Review of data from Phase 1 and interim Phase 2 studies of Camidanlumab tesirine (Cami) in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) and other lymphomas.
  • Analysis of treatment-emergent adverse events (TEAEs), immune-related adverse events (irAEs), overall response rates (ORR), and complete response (CR) rates.

Main Results:

  • In Phase 1, Cami demonstrated encouraging clinical activity in multiply relapsed/refractory cHL, with an ORR of 71% and CR of 40% (n=75).
  • TEAEs occurred in 95% of patients, with grade 3 TEAEs in 66% of cHL patients. Immune-related adverse events (irAEs) were also noted.
  • Interim Phase 2 results showed a higher ORR of 83% and CR of 38% in 47 evaluable cHL patients, with a similar safety profile to Phase 1.

Conclusions:

  • Camidanlumab tesirine (Cami) exhibits promising efficacy and a manageable safety profile in patients with multiply relapsed/refractory classical Hodgkin lymphoma (cHL).
  • Preliminary data suggest Cami represents a valuable additional therapeutic option for patients with advanced cHL and potentially other CD25-expressing hematological malignancies.
  • Further accrual and final results from the ongoing Phase 2 study are anticipated to confirm these encouraging findings.
Keywords:
CamiCamidanlumab TesirineHodgkin lymphomaRefractoryRelapsedcHL

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
864